Regulatory

The war on (some) drugs continues apace. Or is this just a simple administrative maneuver that has everyone paranoid?

As proposed by FDA, the New Dietary Ingredient guidance document could upend the ingredients and supplements world more profoundly than anything this side of 1994's DSHEA.

The FDA opens its Adverse Event Report data with little context and no causality.

Astaxanthin is a solid case study demonstrating the complexity of the FDA’s guidance doc.

New rules, old problems. The NDI guidance challenges the industry to be more responsible.

As the agency takes testimony on the meaning of "healthy" on food labels, it revises its stance on high-fat foods.

A letter to the industry

If you haven’t read all 112 pages of the FDA’s new draft guidance on NDI’s, you’re not alone. If you’re not ready for its full rollout and enforcement, or don’t have a plan to get ready, you’ve got plenty of company in an industry that could soon...

The Food and Drug Administration announced a call for comments on a definition of "healthy" Tuesday.